My issue is not w/ DCvax, we know it’s efficacious. My issue is shareholder dilution and timing — and I get particularly anxious when the dilution seems unnecessary and self serving.
There are biotechs at similar stages of development that use debt funding at commercial terms without all the kickers of discounts and conversion features.
I understand the carrot, but eventually the horse drops dead from exhaustion.
News 
Market Data 
Discover 
